Male
Brian Stuglik was appointed to Chief Executive Officer (CEO) of Verastem Oncology in July, 2019. Mr. Stuglik is a global leader in the oncology pharmaceutical sector with over 3 decades of experience in US and International pharmaceutical development, product strategy, commercialization and business development. He successfully developed, acquired and launched several multi-billion dollar oncology brands across multiple tumor types and therapeutic approaches. Brian founded Proventus Health Solutions, a company specializing in helping oncology biotech companies create greater value by integrating development and commercial considerations into a unified approach. Currently, he serves as a member of the board of directors for Verastem Oncology (VSTM) and Oncopeptides AB (ONCO).
Headlines from Google News. Social posts load from the platform only when you open a tab.
pharmavoice.com · Apr 4
Fierce Biotech · Aug 28
citybiz · Jul 11
PR Newswire · Nov 22
Endpoints News · Feb 28